Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes by Maresh, Michael J A et al.
Glycemic targets in the second and third trimester of pregnancy
for women with type 1 diabetes
Maresh, M. J. A., Holmes, V. A., Patterson, C. C., Young, I. S., Pearson, D. W. M., Walker, J. D., ... Diabetes
and Pre-eclampsia Intervention Trial Study Group (2015). Glycemic targets in the second and third trimester of
pregnancy for women with type 1 diabetes. Diabetes Care, 38(1), 34-42. DOI: 10.2337/dc14-1755
Published in:
Diabetes Care
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2015 American Diabetes Association.
This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes
Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version
derived from it by third parties. The definitive publisher-authenticated version is available online at doi:10.2337/dc14-1755.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
Glycemic targets in the second and third trimester of pregnancy for women with type 1 
diabetes 
 
Short title: Pregnancy glycemic targets in type 1 diabetes 
 
Authors: Michael J.A. Maresh, MD1, Valerie A. Holmes, PhD2, Christopher C. Patterson, 
PhD2, Ian S. Young, MD2, Donald W.M. Pearson, MD3, James D. Walker, MD4, David R. 
McCance, MD5; For the Diabetes and Pre-eclampsia Intervention Trial Study Group 
 
1. Department of Obstetrics, St Mary’s Hospital, Central Manchester University Hospitals 
NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK  
2. Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s 
University Belfast, Belfast, UK 
3. Department of Diabetes, Aberdeen Royal Infirmary, Aberdeen, UK;  
4. Department of Diabetes, St John’s Hospital at Howden, West Lothian, UK 
5. Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK 
 
 
Corresponding author:- 
Dr MJA Maresh, Department of Obstetrics, St Mary’s Hospital, Oxford Road, Manchester 
M13 9WL Tel: 0044 161 276 6426       Fax 0044 161 276 6426   
Email : michael.maresh@cmft.nhs.uk.   
Word count: 3814  
Tables: 4 
Abstract 
 Objective To assess the relationship between second and third trimester glycemic control 
and adverse outcomes in pregnant women with type 1 diabetes, as uncertainty exists about 
optimum glycemic targets.  
Research Design and Methods Pregnancy outcomes were assessed prospectively in 725 
women with Type 1 diabetes from the Diabetes and Pre-eclampsia Intervention Trial. A 
composite adverse outcome of perinatal death, shoulder dystocia, nerve palsy, fracture and 
neonatal intensive care was included. HbA1c (A1C) values at 26 and 34 weeks’ gestation 
were categorised into 5 groups; the lowest, <6.0% (42mmol/mol), being the reference. 
Average pre- and post-prandial results from an eight-point capillary glucose profile the 
previous day were categorised into 5 groups; the lowest (pre-prandial <5.0mmol/l, post-
prandial <6.0mmol/l) being the reference.   
Results An A1C of 6.5-6.9% (48- 52mmol/mol) at 26 weeks’ gestation was associated with a 
significantly increased risk of: pre-term delivery (odds ratio 2.5 [95% CI 1.3-4.8]), pre-
eclampsia (4.3 [1.7-10.8]), large for gestational age (LGA) (2.4 [1.4-4.5]), need for a neonatal 
glucose infusion (2.9 [1.5-5.6]) and a composite adverse outcome (3.2 [1.3-8.0]). The risks 
increased with increasing A1C with no thresholds. Results were similar at 34 weeks’ 
gestation. Glucose data showed less consistent trends, although LGA was associated with 
higher pre- and post-prandial glycemia, and  the risk of composite adverse outcome increased 
with pre-prandial glucose levels between 6.0-6.9mmol/l at 34 weeks (3.3[1.3-8.0]). 
Conclusions A1C≥ 6.5% (48mmol/mol) at 26 and 34 weeks gestation predicts adverse 
outcomes in type 1 diabetes. Regular measurements in pregnancy, with expert surveillance 
when elevated is indicated.  
It is now well established that optimising glycemic control in pregnant women with type 
1diabetes is associated with improved outcomes (1). However, achieving normoglycemia is 
not without risks, particularly those associated with maternal hypoglycemia (2).  
While there is agreement that poor periconceptual glycemic control increases the risk of 
congenital malformations (2), much less consensus exists as to the relation of glycemic 
control later in pregnancy to specific adverse maternal and neonatal outcomes. Possible 
explanations for this lack of consensus include: the small number of randomised controlled or 
prospective observational cohort trials; the retrospective design of most studies, comparison 
of  women with good and poor outcomes; minimal standardisation of  maternal and neonatal 
outcome indicators, including composite outcomes; and comparison of glycemic control in 
different trimesters of pregnancy using different measures of glycemia such as A1C, and 
meal-related (pre, post, average) measures of glycemic control. In addition, these latter 
glycemic measures are usually expressed as arbitrary thresholds such as a dichotomy of good 
or poor control, tertiles of glycemia, or other groupings. 
 
A1C is generally favoured as an estimate of glycemic control as it requires one non-fasting 
blood sample and represents an objective measurement of glycemic control over the 
preceding 6-8 weeks. However, the literature would suggest that there is a fall in A1C during 
pregnancy and that A1C is lower in pregnancy than outside of pregnancy. This requires care 
with interpretation of results. A systematic review of the relationship between A1C and 
adverse outcomes (1) reported that an elevated A1C towards the end of the first trimester 
usually reflects sub-optimal control around the time of conception and in the first trimester, 
and has been associated with an increased incidence of congenital malformations and 
miscarriage (3,4). Some studies in type 1 diabetes reporting A1C values in the second or third 
trimesters, have demonstrated an association between poor control and an increased risk of 
stillbirth (4,5), fetal macrosomia or large for gestational age (LGA) (6-10), neonatal intensive 
care (11) and other adverse outcomes such as preterm delivery(12), pre-eclampsia (13) and 
composite indicators of adverse outcome (14). Several studies in which women were 
randomised to either strict or less strict glycemic control were unable to demonstrate an 
improvement in A1C in the more strictly controlled group (15), however these studies were 
small and as a consequence no definite conclusions on the degree of glycemic control 
necessary to impact on outcomes were reached (16). One non-randomised study suggested 
that very tight control was not necessarily required to obtain satisfactory outcomes, and was 
associated with more maternal hypoglycemia (17). 
 
Reports which have used self-monitored capillary blood glucose as a measure of glycemic 
control have tended to compare women with and without adverse outcomes in relation to 
mean glucose values: either pre-prandial, post-prandial or combined. Karlsson and Kjellmer 
(18) reported that increased rates of poor pregnancy outcomes were associated with 
increasing third trimester mean glucose values. Damm et al. (14) demonstrated that more 
women had poor outcomes when capillary glucose values were outside the normal range. The 
Diabetes in Early Pregnancy Study (6) showed an association between increasing birth 
weight and increasing mean post-prandial, but not pre-prandial glycemia, a finding reported 
elsewhere (19), while other studies suggested a relationship with pre-prandial (20) or mean 
levels (21). Another approach has been to create arbitrary glycemic thresholds such as good 
or poor control and some studies have demonstrated higher neonatal morbidity in the poor 
glycemic control group (22,23). Furthermore, Mello et al. showed that  the risk of LGA was 
increased with poor glycemic control in the second trimester even if  glycemic control was 
good in the third (24). Due to the limitations of self monitoring of glycemic control, Kerssen 
et al. (25) used continuous glucose monitoring and in a small study showed a relationship 
between the median 24 hour glucose level and LGA. Finally, in a randomised controlled trial, 
Manderson et al. (26) highlighted the relevance of post-prandial glycemia to both maternal 
and fetal outcomes.  
 
Although these studies have generally demonstrated an association between suboptimal 
glycemic control and an increased risk of poor pregnancy outcome, they are of limited value 
in informing clinicians about the optimal glycemic targets required to minimise these risks. In 
addition, while it is usually possible with treatment to achieve normoglycemia in gestational 
diabetes and often in type 2 diabetes, this is much more challenging in the pregnant woman 
with type 1 diabetes and must be constantly balanced against the risks of hypoglycemia. 
Various guidelines for glycemic control in pregnancy have been proposed. The American 
Diabetes Association (27) recommends a target A1C below 7% (53 mmol/mol) prior to 
conception, similar to that recommended in Scotland (28). In the rest of the UK, the National 
Institute of Clinical Excellence (NICE) guidelines (29) recommend a target A1C of 6.1% or 
below (43 mmol/mol) prior to conception, if this can be achieved safely.  During pregnancy 
the A1C target in the US is 6.0% (307) with monitoring every 1-3 months.  In contrast, UK 
NICE guidelines advise against routine measurement of A1C in the second and third 
trimester (29), apparently because of lack of evidence and physiological changes in 
pregnancy.   With regard to glycemic targets, there is fairly close agreement in the US and 
UK guidelines, with the US advising pre-prandial values 3.3-5.4 mmol/l (60-99mg/dl) and 
peak post-prandial values between 5.4-7.1 mmol/l (100-129mg/dl) (30), while the UK NICE 
guidelines recommend pre-prandial capillary glucose target values between 3.5 to 5.9 mmol/l 
and one hour post-prandial values below 7.8 mmol/l (29).  While there is good evidence to 
support the statement that poor pregnancy outcomes are more likely to be associated with 
sub-optimal glycemic control during pregnancy, there is actually minimal data to inform 
clinical targets for either A1C or glucose and so to date, guidelines  have been based mainly 
on expert opinion.  
 
Given this background, the aim of this study was to assess the relationship between glycemic 
control, as assessed by both A1C and capillary blood glucose profiles in the second and third 
trimesters of pregnancy, and maternal and neonatal outcomes, in a large prospective cohort of 
women with type 1 diabetes.  
 Methods 
The study population comprised 762 women with type 1 diabetes recruited from 25 joint 
antenatal-metabolic clinics across Northern Ireland, North West England and Scotland 
between April 2003 and June 2008 into the Diabetes and Pre-eclampsia Intervention Trial 
(DAPIT). DAPIT was a multi-centre randomised, placebo-controlled trial of Vitamin C and E 
supplementation to prevent pre-eclampsia in pregnant women with type 1 diabetes. As no 
effect of antioxidant vitamins on the development of pre-eclampsia was demonstrated, the 
active treatment and placebo groups were combined for analysis (31).   
 
Details of the methodology have been described previously (13, 31). In brief, women with 
type 1 diabetes were recruited between 8-22 weeks gestation and randomised to vitamin C 
and E supplementation or matched placebo. 762 women were recruited, with 749 women 
progressing to at least 20 weeks’ gestational age. The 725 women who subsequently 
delivered an infant without a major malformation were included in this analysis. At the first 
antenatal-metabolic clinic visit, details including ethnicity, parity, years of education, social 
class and smoking habits were recorded and BMI and A1C measured. Subsequently women 
were reviewed at 26 (±2) weeks’ gestation and at 34 (±2) weeks’ gestation when venous 
blood samples were obtained for measurement of A1C. The samples were stored at -70⁰C for 
transportation to the Nutrition and Metabolism Laboratories, Queen’s University Belfast and 
batch assayed at the end of the study. A1C (Diazyme Laboratories, Poway, CA) was 
measured by spectrophotometry using an automated ILab600 biochemical analyser. As a 
National Glycohaemoglobin Standardization Program and International Federation for 
Clinical Chemistry certified method, the values reported were aligned with the Diabetes 
Control and Complications Trial system, with intra- and interassay coefficients of variation 
<2%. A1C results were arbitrarily grouped by 0.5% intervals from <6.0 (42mmol/mol) to 
≥7.5% (59mmol/mol), with <6.0% (42mmol/mol) taken as the reference group. All women 
were requested to measure their capillary blood glucose on a standardised meter 8 times a day 
(pre and 1h post meals and at bedtime) and to record the values on the day prior to the 26 and 
34 week study visit. The mean of the fasting/pre-prandial values and the mean of the post-
prandial values were analysed in relation to 1 mmol/l increments; for pre-prandial the range 
was from < 5.0 to ≥8.0 mmol/l and for post-prandial <6.0 to ≥9.0mmol/l. The lowest group in 
both cases was taken as the reference. 
 
Maternal and neonatal outcomes were as previously specified (31), but only a selection has 
been analysed here. Pre-eclampsia, was defined as gestational hypertension and proteinuria in 
accordance with the International Society for the Study of Hypertension in Pregnancy (32). 
Birthweight centiles were calculated using customised birthweight charts (33) and those >90th 
centile classified as large for gestational age (LGA). Admission to a neonatal unit was 
defined as either high dependency or intensive care (levels 2 and 3), with these levels of care 
being rigorously defined. Neonatal hypoglycemia was defined by the need for an intravenous 
glucose infusion and neonatal hyperbilirubinaemia by the need for phototherapy. In addition 
caesarean delivery and gestation at delivery were also considered. As serious adverse 
outcomes are rare, a composite outcome variable composed of several individual adverse 
endpoints was also included. Unfortunately no such standardised outcome exists in the 
literature and neither was one specified in the DAPIT study. The composite outcome 
employed here was adapted from that used in the ACHOIS study (34) (namely perinatal 
death, shoulder dystocia, fractures or nerve palsy), with the addition of admission to the 
neonatal intensive care unit for level 2 or 3 care.  
 The West Midlands Multicentre Research Ethics Committee provided ethical approval 
(MREC 02/7/016). The study was registered as an International Standard Randomised 
Controlled Trials, ISRCTN 27214045. 
 
Statistical analysis 
Comparisons of outcomes in groups defined by A1C levels or by averaged capillary blood 
glucose levels at 26 or 34 weeks were performed using the χ2 test for trend in contingency 
tables. Logistic regression was used to estimate the odds of outcomes in each group relative 
to the group with lowest A1C or averaged glucose values, with results expressed as odds 
ratios with 95% confidence intervals. This was done both before and after adjustment for 
potentially confounding variables (age, BMI, ethnicity, diabetes duration, parity, current 
smoking, years of education, social class, plasma ascorbate and serum α-tocopherol at 
randomisation, microalbuminuria before pregnancy, vitamin treatment group and center).  All 
statistical analyses were performed using SPSS software, version 20 (IBM Corp., Armonk, 
NY, USA).  
 
 
Results  
Maternal characteristics and glycemic control are shown in Table 1. Further characteristics 
have previously been described in detail (31). 
 
A1C results were available for 576 (79%) and 505 (70%) participants at 26 and 34 weeks’ 
gestation, respectively. Maternal and neonatal outcomes by A1C groups are described in 
Tables 2 and 3, showing both the unadjusted and adjusted rates allowing for specific 
confounders. With higher values of A1C there were increasing risks of pre-eclampsia, pre-
term delivery, LGA, neonatal hypoglycemia requiring a glucose infusion, 
hyperbilirubinaemia requiring phototherapy and a composite adverse outcome.  The less 
common  outcomes of birthweight <10th centile (rate 3%) and Apgar score at 5 minutes < 7 
(rate 2%) were also investigated, and no significant relationship found. Ethnicity had no 
effects on outcomes. Allowing for A1C values in the first or early second trimester of 
pregnancy had a slight modifying effect on the degree of significance of some of the 
outcomes, but the trends remained (Supplemental Tables S1and S2)).  
The A1C measurements at 26 and 34 weeks were strongly correlated (r=0.8) resulting in the 
associations between A1C at 34 weeks and adverse outcomes,  adjusted for A1C at 26 weeks, 
being weakened and in many cases non-significant; a similar finding occurred with analysis 
of A1C at 26 weeks adjusting for A1C at 34 weeks (data not shown). However,  the 41 
women with A1C ≥6.5% (48mmol/mol) in the second trimester, but < 6.5% (48mmol/mol) in 
the third, had significantly fewer LGA babies (p=0.033) with a trend towards fewer adverse 
composite outcomes (p=0.065) and cases of preterm delivery (p=0.064) compared with those 
women whose A1c remained ≥6.5% (48mmol/mol) in both trimesters (n=191). However, the 
number of subjects was small and the data need to be interpreted with caution.   
 Comparison of the women with and without A1C measurements at 26 and 34 weeks showed 
some differences with regard to maternal age in that the women with missing data were about 
1 year younger (although of similar BMI, diabetes duration and total daily dose of insulin), 
and they were also recruited about 1 week later. In addition at 34 weeks there were 
significantly more nulliparous women with missing data, but there was no difference at 26 
weeks.    
Average pre-/post-prandial capillary blood glucose results were available for 610 (84%)/484 
(67%) and 546 (75%)/447 (62%) participants at 26 and 34 weeks’, respectively. The maternal 
and neonatal outcomes according to capillary blood glucose categories are shown in Table 4 
and Supplemental Tables S3-5. Significant linear trends were demonstrated for LGA with 
pre-prandial glycemia at both 26 (p<0.001) and 34 (p<0.05) weeks’ gestation. For post-
prandial glycemia significant trends for LGA were again demonstrated at 26 (p<0.03) and 34 
(p<0.02) weeks’ gestation. No other significant trends were demonstrated for post-prandial 
glycemia (Supplemental Tables S 4, 5). However, increasing pre-prandial glycemia was also 
associated with significantly increasing rates of preterm delivery at both 26 weeks’ (OR 2.0, 
95% CI 1.1-3.7 when glucose 7.0-7.9mmol/l) and at 34 weeks’ (OR 2.4, 95% CI 1.2-5.0 
when glucose≥8.0mmol/l) (Table 4 and Supplemental Table 3). Other significant associations 
with pre-prandial glycemia at 34 weeks were also demonstrated (Table 4). 
 Conclusions 
This large, prospective study of women with type 1 diabetes has demonstrated a relationship 
between increasing A1C categories during the second and third trimesters of pregnancy and a 
series of relevant, rigorously defined adverse maternal and neonatal outcomes including a 
composite neonatal outcome. Unlike previous data, this study gives a much clearer picture of 
the A1C and capillary glucose targets which should be aimed for to minimise the risk of 
adverse outcomes. 
While a randomised controlled trial is the gold standard for looking at the association 
between varying degrees of glycemic control and adverse pregnancy outcomes such a design 
is impractical and most likely unethical. Previous studies have been too small (16, 17) to 
examine the main outcomes included in the current study, and thus only a large prospective 
observational study would appear feasible. Although the primary outcome of the DAPIT trial 
was pre-eclampsia, prospective documentation of other pre-specified outcomes, together with 
A1C measurements in each trimester, permitted utilisation of this valuable cohort of subjects 
with type 1 diabetes to examine the important question of the relationship between glycemic 
control in later pregnancy and maternal and neonatal outcomes.  However, given the rarity of 
outcomes such as perinatal death and birth trauma, prior to data analysis, we considered it 
necessary to derive a composite adverse neonatal outcome which we defined as that used in 
the ACHOIS study (34), combined with need for  admission to level 2 or level 3 neonatal 
intensive care as defined in the DAPIT trial.   Prior to data analysis, A1C and blood glucose 
categories were also agreed. 
The association of increasing A1C in early pregnancy and the risk of miscarriage and 
congenital anomalies is well established (35). However, while a number of studies have 
shown an association between deteriorating glycemic control and an increased risk of adverse 
outcomes, few have data relating specific A1C target values later in pregnancy with adverse 
outcomes, and some national guidelines question the clinical utility of A1C measurements 
outside the first trimester. Indeed in the UK, the current NICE guidelines suggest that A1C 
should not be measured in the second and third trimester (29), presumably on the basis of 
lack of evidence to support its measurement and concern regarding interpretation of the result 
given the physiological fall in A1C during pregnancy. The present study has clearly 
demonstrated an increased risk of adverse outcomes in later pregnancy with increasing A1C 
values. Tennant and colleagues (5) showed an increasing rate of stillbirths and neonatal 
deaths with increasing maternal A1C. However, our data  has the advantage of being 
collected prospectively and includes the examination of a wide range of maternal and 
neonatal outcomes by specific target ranges of A1C and pre- and post-prandial capillary 
blood glucose measurements. In addition, unlike most previous studies, pregnancies 
complicated by a major congenital anomaly were excluded to focus on adverse outcomes 
associated with glycemic control in the second and third trimester. 
We found a striking linear relationship between A1C categories and the composite adverse 
neonatal outcome, and even for A1C 6.5-6.9% (48-52mmol/mol) the risk was significantly 
increased at 26 and 34 weeks’ gestation. Macrosomia, is a commonly reported outcome 
which has previously been associated with increasing A1C (6-10), and we have shown a clear 
association with the strict definition of birthweight >90thcentile (LGA), using customised 
birthweight charts. There was a linear trend with increasing A1C, and a significant increase in 
LGA even for the A1C category 6.0-6.4% (42-47mmol/mol) both at 26 and 34 weeks’ 
gestation. Neonatal hypoglycemia is an indicator of maternal antenatal glycemic control, but 
is difficult to standardise because of differing definitions and sampling times. Accordingly, 
we utilised a more robust measure, namely treatment with an intravenous glucose infusion, 
and found a linear increase in neonatal hypoglycemia with increasing A1C, a significant 
increase being present for A1C between 6.5-6.9% (48-52mmol/mol). Similar relationships 
were demonstrated with preterm delivery.  Hyperbilirubinemia, a recognised neonatal 
complication of the baby born to a mother with diabetes, and not reported in other studies, 
also showed a linear trend with increasing maternal A1C, although significance was not 
apparent until A1C ≥ 7.0% (53mmol/mol). A previous analysis of the DAPIT cohort, showed 
an increasing risk of pre-eclampsia with increasing A1C (13) and further analysis here 
showed  a significant increased risk with A1C ≥ 6.5% (48mmol/mol) at 26 and 34 weeks’ 
gestation. Furthermore, we found that the relationships between the adverse outcomes and 
A1C values in the second and third trimesters persisted even after controlling for A1C in the 
first or early second trimester. Increasing A1C values had no apparent impact on cesarean 
section rates, perhaps not surprising given the many factors which contribute to this outcome. 
  
Our study indicates the clinical utility of regular A1C measurements throughout pregnancy in 
predicting whether a woman is at an increased risk of an adverse outcome.  While 
measurement of A1C does not necessarily motivate behaviour change, our data does suggest 
that A1C values ≥ 6.5% (48mmol/mol), identify women at increased risk of adverse 
outcomes. This was shown particularly at 26 weeks, but less so at 34 weeks. Clinically, these 
findings would support regular measurement of A1C every 1-3 months throughout pregnancy 
as advised in the US (30). ). Our data shows that for some outcomes such as LGA, the risk is 
already present when the A1C is ≥ 6.0% (42mmol/mol), but such values may not be 
achievable in routine practice because of hypoglycaemia and targets must be realistic and 
individualised. However, the data indicate that those women with A1C values in the second 
trimester ≥6.5% (48mmol/mol) need to be counselled about the increased risk of adverse 
outcomes. The risks of stillbirth are present throughout the third trimester (36) and if A1C is 
≥ 6.5% (48mmol/mol), such women require intensive supervision by experienced clinicians. 
This may include more frequent clinic visits and in some women even a short period of 
hospitalisation. We also suggest that ultrasound scans should be performed more frequently 
than the 4 weekly interval, as currently recommended by NICE (29) with careful review of 
the results, as poor data interpretation was found to be associated with an increased risk of 
adverse outcomes (37). In the US, more detailed fetal assessment including biophysical 
profile testing, cardiotocography and Doppler umbilical artery velocimetry have been advised 
for most patients from about 32 weeks (38), although the benefits of such detailed 
assessments remain   unclear.  
On a day to day basis, however, it is the results of pre- and post-prandial monitoring, rather 
than monthly A1C results, which provide immediate feedback on glucose excursions and 
guide insulin adjustment. This study has allowed investigation of the effect of varying 
degrees of glycemia in the second and third trimester on specific maternal and neonatal 
outcomes.  Self reported measurements do have limitations and in this study pertained to one 
particular day in the second and third trimester. While a significant number of women had 
missing data, and there were some differences in the characteristics of women with and 
without readings, it seems unlikely that these differences would have significant clinical 
implications. We are unaware of other studies of this size which have considered multiple 
maternal and neonatal outcomes in relation to such an extensive dataset of glucose measures 
and it is probable that none will be forthcoming until results from large studies using 
continuous glucose monitoring become available, although smaller studies have revealed an 
association with LGA babies (25). While the relationship between glucose data and adverse 
outcomes does not show such a clear trend as with A1C, there was evidence of an increased 
linear risk of LGA with both pre- and post-prandial glucose concentrations. This is in accord 
with previous studies which have shown relationships with pre-prandial glycemia (20), post-
prandial glycemia (7, 19) and mean glucose levels (21, 24, 25). In the present study, a 
number of neonatal adverse outcomes were significantly related to pre-prandial rather than 
post-prandial values particularly at the 34 weeks’ gestation time point. These included the 
composite adverse neonatal outcome, neonatal hypoglycemia requiring a glucose infusion, 
hyperbilirubinaemia requiring phototherapy and preterm delivery. We are not aware of other 
studies which have reported an association between these outcomes and worsening pre-
prandial glycemic control. These results suggest that glycemic control during fasting and pre-
prandial periods may be more relevant to adverse outcomes than the shorter post-prandial 
periods of hyperglycemia. 
 
In summary, the current study has shown a continuous  relationship between multiple 
maternal and neonatal adverse outcomes and increasing A1C values in the second and third 
trimester of pregnancy in women with type 1 diabetes. These adverse outcomes were 
significantly associated with A1C of ≥6.5% (48mmol/mol) and LGA with an A1C ≥6.0% 
(42mmol/mol). We feel that women should be advised to aim for target values of <6.5% 
(48mmol/mol) and ideally <6.0% (42mmol/mol) if this is possible without excessive 
hypoglycemia. For women in whom this goal is not achieved, additional surveillance by 
experienced clinicians is indicated. While capillary blood glucose data were generally 
concordant with the A1C results, it was not possible to define a clear target range, although 
third trimester pre-prandial glucose values between 6.0- 6.9mmol/l were associated with an 
increased risk of an adverse composite neonatal outcome. This is in agreement with current 
ADA and NICE guidelines which recommend pre-prandial glucose values of <5.5 and 
<6.0mmol/l, respectively (27,29). Finally, our data suggest that current UK NICE guidelines, 
with regard to the usefulness of A1C in later pregnancy, need to be reviewed. 
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Age (years) mean (SD) 29.6 (5.6)  
Body Mass Index (kg m-2) mean (SD) * 27.4 (4.7) 
Diabetes duration (yr) mean (SD) 14.5 (8.2) 
Primiparous n (%) 361 (49.8%) 
Smoker n (%) 139 (19.2%) 
Social class – head of household in professional or managerial/ 
technical occupation n (%) † 
297 (46.0%) 
Non-white ethnicity n (%)   26 (3.6%) 
Education (yr) mean(SD)  14.0 (2.8) 
A1C (%: mmol/mol) mean (SD) ‡   
       First antenatal visit 7.8 (1.4): 62 (15)   
       26 weeks gestation 6.7 (0.8): 50 (9)   
       34 weeks gestation 6.6 (0.7): 48 (7)   
Mean fasting/pre-prandial capillary glucose (mmol/l) mean (SD) §  
       26 weeks gestation 6.4 (1.8) 
       34 weeks gestation 6.0 (1.7) 
Mean 1 hour post-prandial capillary glucose (mmol/l) mean (SD)║   
       26 weeks gestation 7.5 (2.4) 
       34 weeks gestation 7.2 (2.3) 
*Based on n=708 results 
† Based on n=646 results 
‡ Based on n= 698/576/505 results at first antenatal visit/26 weeks gestation/34 weeks gestation  
§ Based on n= 610/546 results at 26weeks gestation/34 weeks gestation 
║ Based on n= 484/447 results at 26weeks gestation/34 weeks gestation 
Table 1: Maternal characteristics and glycemic control in 725 participants 
 
 
 A1C at 26 weeks 
<6.0 % 
(<42 mmol/mol) 
6.0-6.4% 
(42-47 mmol/mol) 
6.5-6.9% 
(48-52 mmol/mol) 
7.0-7.4% 
(53-58 mmol/mol) 
7.5+ % 
(59+ mmol/mol) 
P value 
n = 101  n = 176  n = 128  n = 98  n = 73  for trend 
Pre-eclampsia  Number (%)   8/101 (8%) 23/176 (13%) 29/128 (23%) 24/98 (24%) 17/73 (23%)  
OR (95%CI) 
OR (95%CI) *   
1.0 
1.0 
reference 
reference 
1.7 
2.0 
(0.8, 4.1) 
(0.8, 4.9) 
3.4‡ 
4.3‡ 
(1.5, 7.8) 
(1.7,10.8) 
3.8‡ 
4.6‡ 
(1.6, 8.9) 
(1.8,12.0) 
3.5‡ 
5.1‡ 
(1.4, 8.7) 
(1.9,14.1) 
<0.001 
<0.001 
Large for gestational 
 age (>90th centile) 
Number (%) 36/99 (36%) 88/175 (50%) 73/128 (57%) 60/98 (61%) 46/73 (63%)  
OR (95%CI) 
OR (95%CI) *  
1.0 
1.0 
reference 
reference 
1.8† 
1.7† 
(1.1, 2.9) 
(1.0, 3.0) 
2.3‡ 
2.5‡ 
(1.4, 4.0) 
(1.4, 4.5) 
2.8§ 
3.2§ 
(1.6, 4.9) 
(1.7, 6.1) 
3.0§ 
3.7§ 
(1.6, 5.6) 
(1.8, 7.5) 
<0.001 
<0.001 
Cesarean section  
delivery 
Number (%) 67/101 (66%) 125/176 (71%) 85/128 (66%) 76/98 (78%) 46/73 (63%)  
OR (95%CI) 
OR (95%CI) * 
1.0 
1.0 
reference 
reference 
1.2 
1.1 
(0.7, 2.1) 
(0.6, 2.0) 
1.0 
1.1 
(0.6, 1.7) 
(0.6, 2.0) 
1.8 
2.0 
(0.9, 3.3) 
(1.0, 3.9) 
0.9 
1.0 
(0.5, 1.6) 
(0.5, 1.9) 
0.90 
0.48 
Neonatal hypoglycemia 
requiring glucose  
infusion 
Number (%) 20/99 (20%) 42/170 (25%) 49/124 (40%) 39/95 (41%) 30/70 (43%)  
OR (95%CI) 
OR (95%CI) * 
1.0 
1.0 
reference 
reference 
1.3 
1.5 
(0.7, 2.4) 
(0.8, 2.9) 
2.6‡ 
2.9‡ 
(1.4, 4.7) 
(1.5, 5.6) 
2.8‡ 
3.5§ 
(1.5, 5.2) 
(1.7, 7.2) 
3.0‡ 
3.8§ 
(1.5, 5.9) 
(1.7, 8.2) 
<0.001 
<0.001 
Hyperbilirubinemia 
requiring phototherapy 
Number (%) 13/99 (13%) 25/173 (14%) 26/127 (20%) 28/96 (29%) 20/71 (28%)  
OR (95%CI) 
OR (95%CI) *  
1.0 
1.0 
reference 
reference 
1.1 
1.4 
(0.5,2.3) 
(0.6, 2.9) 
1.7 
2.1 
(0.8, 3.5) 
(0.9, 4.5) 
2.7‡ 
3.7‡ 
(1.3, 5.7) 
(1.7, 8.3) 
2.6† 
3.8‡ 
(1.2, 5.7) 
(1.6, 8.9) 
<0.001 
<0.001 
Delivery before 37 weeks Number (%) 21/101 (21%) 51/176 (29%) 48/128 (38%) 50/98 (51%) 33/73 (45%)  
OR (95%CI) 
OR (95%CI) * 
1.0 
1.0 
reference 
reference 
1.6 
1.6 
(0.9, 2.8) 
(0.8, 2.9) 
2.3‡ 
2.5‡ 
(1.3, 4.2) 
(1.3, 4.8) 
4.0§ 
5.1§ 
(2.1, 7.4) 
(2.6,10.2) 
3.1§ 
3.8§ 
(1.6, 6.1) 
(1.8, 8.0) 
<0.001 
<0.001 
Composite adverse  
neonatal outcome  
 
Number (%) 8/101 (8%) 21/176 (12%) 25/128 (20%) 27/98 (28%) 16/73 (22%)  
OR (95%CI) 
OR (95%CI) * 
1.0 
1.0 
reference 
reference 
1.6 
1.6 
(0.7, 3.7) 
(0.7, 4.1) 
2.8† 
3.2‡ 
(1.2, 6.6) 
(1.3, 8.0) 
4.4§ 
6.7§ 
(1.9,10.3) 
(2.6,17.0) 
3.3† 
4.4‡ 
(1.3, 8.1) 
(1.6,12.3) 
<0.001 
<0.001 
† P<0.05, ‡ P<0.01, § P<0.001 
* Adjusted for age, body mass index, years of education, social class, ethnicity, parity, current smoking, duration of diabetes, microalbuminuria before pregnancy, vitamin 
treatment group and center. 
 
Table 2   Adverse pregnancy outcomes by A1C category at 26 weeks gestation 
 
 A1C at 34 weeks  
<6.0 % 
(<42 mmol/mol) 
6.0-6.4% 
(42-47 mmol/mol) 
6.5-6.9% 
(48-52 mmol/mol) 
7.0-7.4% 
(53-58 mmol/mol) 
7.5+ % 
(59+ mmol/mol) 
P value 
n = 98  n = 165  n = 136  n = 66  n = 40  for trend 
Pre-eclampsia  Number (%) 8/98 (8%) 23/165 (14%) 19/136 (14%) 12/66 (18%) 11/40 (28%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.8 
2.4 
(0.8, 4.3) 
(0.9, 6.3) 
1.8 
3.0† 
(0.8, 4.4) 
(1.1, 7.9) 
2.5 
5.3‡ 
(1.0, 6.5) 
(1.7,16.9) 
4.4‡ 
6.8‡ 
(1.6,11.6) 
(2.1,22.8) 
0.005 
<0.001 
Large for gestational  
age  (>90th centile) 
Number (%) 33/98 (34%) 77/165 (47%) 91/136 (67%) 44/65 (68%) 21/40 (53%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.7† 
1.9† 
(1.0, 2.9) 
(1.1, 3.3) 
4.0§ 
4.6§ 
(2.3, 6.9) 
(2.5, 8.5) 
4.1§ 
5.6§ 
(2.1, 8.0) 
(2.6, 12.0) 
2.2† 
2.9† 
(1.0, 4.6) 
(1.3, 6.7) 
<0.001 
<0.001 
Cesarean section  
delivery 
Number (%) 62/98 (63%) 107/165 (65%) 99/136 (73%) 51/66 (77%) 23/40 (58%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.1 
0.9 
(0.6, 1.8) 
(0.5, 1.7) 
1.6 
1.7 
(0.9, 2.7) 
(0.9, 3.2) 
2.0 
2.4† 
(1.0, 4.0) 
(1.1, 5.4) 
0.8 
0.7 
(0.4, 1.8) 
(0.3, 1.7) 
0.35 
0.26 
Neonatal hypoglycemia 
requiring glucose infusion 
Number (%) 18/97 (19%) 39/158 (25%) 45/133 (34%) 25/64 (39%) 17/38 (45%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.4 
1.7 
(0.8, 2.7) 
(0.9, 3.5) 
2.2† 
2.8‡ 
(1.2, 4.2) 
(1.4, 5.8) 
2.8‡ 
4.1‡ 
(1.4, 5.8) 
(1.8, 9.8) 
3.6‡ 
4.8‡ 
(1.6, 8.1) 
(1.9,12.4) 
<0.001 
<0.001 
Hyperbilirubinemia 
requiring phototherapy 
Number (%) 11/98 (11%) 24/162 (15%) 17/134 (13%) 16/65 (25%) 13/39 (33%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.4 
1.7 
(0.6, 2.9) 
(0.7, 3.9) 
1.1 
1.3 
(0.5, 2.6) 
(0.5, 3.3) 
2.6† 
3.0† 
(1.1, 6.0) 
(1.1, 7.9) 
4.0‡ 
5.4‡ 
(1.6, 9.9) 
(1.9,15.5) 
0.002 
0.002 
Delivery before 37 weeks Number (%) 17/98 (17%) 38/165 (23%) 48/136 (35%) 27/66 (41%) 16/40 (40%)  
OR (95%CI) 
OR (95%CI*  
1.0 
1.0 
reference 
reference 
1.4 
1.4 
(0.8, 2.7) 
(0.7, 2.9) 
2.6‡ 
3.0‡ 
(1.4, 4.9) 
(1.5, 6.1) 
3.3‡ 
4.2§ 
(1.6, 6.8) 
(1.8, 9.7) 
3.2‡ 
4.0‡ 
(1.4, 7.2) 
(1.6,10.4) 
<0.001 
<0.001 
Composite adverse 
neonatal outcome  
 
Number (%) 7/98 (7%) 14/165 (8%) 20/136 (15%) 13/66 (20%) 12/40 (30%)  
OR (95%CI) 
OR (95%CI)* 
1.0 
1.0 
reference 
reference 
1.2 
1.4 
(0.5, 3.1) 
(0.5, 4.0) 
2.2 
2.7 
(0.9, 5.5) 
(1.0, 7.5) 
3.2‡ 
5.5‡ 
(1.2, 8.5) 
(1.7,17.6) 
5.6‡ 
9.4§ 
(2.0,15.5) 
(2.8,31.2) 
<0.001 
<0.001 
 
† P<0.05, ‡P<0.01, § P<0.001 
* Adjusted for age, body mass index, years of education, social class, ethnicity, parity, current smoking, duration of diabetes, microalbuminuria before pregnancy, vitamin 
treatment group and center. 
 
Table 3   Adverse pregnancy outcomes by A1C category at 34 weeks gestation 
 
 Pre-prandial average glucose at 34 weeks 
<5.0 mmol/l 5.0-5.9 mmol/l 6.0-6.9 mmol/l 7.0-7.9 mmol/l 8.0+ mmol/l P value 
n = 158  n = 176  n = 90  n = 64  n = 58   for trend  
Pre-eclampsia  Number (%) 20/158 (13%) 25/176 (14%) 15/90 (17%) 11/64 (17%) 9/58 (15.5%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.1 
1.0 
(0.6, 2.1) 
(0.5, 2.0) 
1.4 
1.2 
(0.7, 2.9) 
(0.5, 2.6) 
1.4 
1.3 
(0.6, 3.2) 
(0.5, 3.3) 
1.3 
1.3 
(0.5, 3.0) 
(0.5, 3.3) 
0.37 
0.44 
Large for gestational age 
 (>90th centile) 
Number (%) 74/158 (47%) 96/175 (55%) 49/90 (54%) 33/64 (52%) 37/58 (64%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.4 
1.4 
(0.9, 2.1) 
(0.9, 2.2) 
1.4 
1.4 
(0.8, 2.3) 
(0.8, 2.4) 
1.2 
1.1 
(0.7, 2.2) 
(0.6, 2.1) 
2.0†  
2.5‡ 
(1.1, 3.7) 
(1.2, 5.0) 
0.07 
0.05 
Cesarean section delivery Number (%) 103/158 (65%) 118/176 (67%) 61/90 (68%) 42/64 (66%) 45/58 (78%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.1 
0.9 
(0.7, 1.7) 
(0.6, 1.5) 
1.1 
1.0 
(0.6, 1.9) 
(0.6, 1.9) 
1.0 
0.9 
(0.6, 1.9) 
(0.5, 1.8) 
1.8 
1.5 
(0.9, 3.7) 
(0.7, 3.1) 
0.19 
0.45 
  Neonatal hypoglycaemia 
requiring glucose infusion 
Number (%) 33//155 (21%) 47/173 (27%) 26/86 (30%) 22/63 (35%) 20/55 (36%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.4 
1.4 
(0.8, 2.3) 
(0.8, 2.5) 
1.6 
1.7 
(0.9, 2.9) 
(0.9, 3.4) 
2.0† 
1.9 
(1.0, 3.8) 
(0.9, 3.9) 
2.1† 
1.9 
(1.9, 4.1) 
(0.9, 4.0) 
0.009 
0.04 
Hyperbilirubinaemia 
requiring phototherapy 
Number (%) 14/157 (9%) 30/175 (17%) 14/87 (16%) 12/64 (19%) 11/57 (19%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
2.1† 
2.1† 
(1.1, 4.2) 
(1.0, 4.3) 
2.0 
2.0 
(0.9, 4.3) 
(0.9, 4.7) 
2.4† 
2.8† 
(1.0, 5.4) 
(1.1, 6.9) 
2.4† 
2.9† 
(1.0, 5.8) 
(1.1, 7.4) 
0.04 
0.02 
Delivery before 37 weeks Number (%) 31/158 (20%) 55/176 (31%) 25/90 (28%) 19/64 (30%) 22/58 (38%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
1.9† 
1.6 
(1.1, 3.1) 
(0.9, 2.7) 
1.6 
1.5 
(0.9, 2.9) 
(0.8, 2.9) 
1.7 
1.6 
(0.9, 3.4) 
(0.8, 3.2) 
2.5‡ 
2.4† 
(1.3, 4.8) 
(1.2, 5.0) 
0.02 
0.03 
Composite adverse neonatal 
outcome  
 
Number (%) 11/158 (7%) 23/176 (13%) 15/90 (17%) 9/64 (14%) 13/58 (22%)  
OR (95%CI) 
OR (95%CI)*  
1.0 
1.0 
reference 
reference 
2.0 
1.9 
(0.9, 4.3) 
(0.8, 4.2) 
2.7† 
3.3‡ 
(1.2, 6.1) 
(1.3, 8.0) 
2.2 
2.6 
(0.9, 5.6) 
(1.0, 7.2) 
3.9‡ 
5.6§ 
(1.6, 9.2) 
(2.1,14.5) 
0.003 
<0.001 
 
† P<0.05, ‡ P<0.01, § P<0.001 
*Adjusted for age, body mass index, years of education, social class, ethnicity, parity, current smoking, duration of diabetes, microalbuminuria before pregnancy, vitamin 
treatment group and center. 
 
Table 4   Adverse pregnancy outcomes by average pre-prandial glucose category at 34 weeks gestation 
 
